Evidence map›Paper›PMID 26956260›Full record

ArticleStroke2016

Fibroblast Growth Factor 23 Is Associated With Subclinical Cerebrovascular Damage: The Northern Manhattan Study.

Clinton B Wright, Nirav H Shah, Armando J Mendez, Janet T DeRosa, Mitsuhiro Yoshita, Mitchell S V Elkind, Ralph L Sacco, Charles DeCarli, Tatjana Rundek, Shonni Silverberg and 2 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Phosphate Dysregulation and Neurocognitive Sequelae.Advances in experimental medicine and biology · 2022
    Article
  8. KernelizedFrontiers in neuroscience · 2021
    Article
  9. Review
  10. Observational
  11. Review
  12. Article
  13. Article
  14. Paracrine Effects of FGF23 on the Heart.Frontiers in endocrinology · 2018
    Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Clinton B WrightFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.). wright.clinton@gmail.com.
Nirav H ShahFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Armando J MendezFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Janet T DeRosaFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Mitsuhiro YoshitaFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Mitchell S V ElkindFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Ralph L SaccoFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Charles DeCarliFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Tatjana RundekFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Shonni SilverbergFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Chuanhui DongFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
Myles WolfFrom the Evelyn F. McKnight Brain Institute (C.B.W., N.H.S., R.L.S., T.R., C.D.) and the Departments of Neurology (C.B.W., R.L.S., T.R., C.D.), Public Health Sciences (C.B.W., R.L.S., T.R.), Human Genomics (R.L.S., T.R.), Medicine (A.J.M.), and the Neuroscience Program (C.B.W., R.L.S.), Leonard M. Miller School of Medicine, University of Miami, FL; Department of Neurology, University of California, San Francisco (N.H.S.); Department of Neurology, College of Physicians and Surgeons, and Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY (J.T.D., M.S.V.E., S.S.); National Hospital Organization, Hokuriku National Hospital, Japan (M.Y.); Department of Neurology, University of California at Davis Health System, Sacramento (C.D.); Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL (M.W.).
National Hospital Organization · JPColumbia University · USUniversity of California, San Francisco · US

Funding

UC Davis Alzheimer's Disease Core CenterP30AG010129 · NIA · UNIVERSITY OF CALIFORNIA DAVIS · PI MEYER, OANH L · 1991 to 2020
$28.3M
PRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Hugo Javier Aparicio, Jose Rafael Romero · 1985 to 2026
$22.9M
STROKE INCIDENCE AND RISK FACTORS IN A TRI-ETHNIC REGIONR01NS029993 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ELKIND, MITCHELL S, SACCO, RALPH L. · 1993 to 2019
$19.2M
Stroke Incidence and Risk Factors in a Tri-Ethnic RegionR37NS029993 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ELKIND, MITCHELL S, SACCO, RALPH L. · 2008 to 2014
$12.1M
FGF-23 and the Risk of Stroke and Cognitive DeclineR01HL108623 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WRIGHT, CLINTON B · 2012 to 2015
$1.7M
Genetics Determinants of Extreme Phenotypes of Subclinical AtherosclerosisK24NS062737 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI RUNDEK, TATJANA · 2009 to 2013
$975k
Mentored Patient Oriented Research in Mineral MetabolismK24DK093723 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI WOLF, MYLES S · 2012 to 2016
$803k
Vascular Determinants of Dementia and Cognitive Decline in a Tri-Ethnic RegionR56NS029993 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI ELKIND, MITCHELL S, RUNDEK, TATJANA · 2021 to 2021
$537k
NHLBI NIH HHS R01 HL108623NIA NIH HHS P30 AG010129NIDDK NIH HHS K24 DK093723NIDDK NIH HHS K24DK093723NINDS NIH HHS K24 NS 062737NINDS NIH HHS K24 NS062737NINDS NIH HHS R01 NS017950NINDS NIH HHS R01 NS029993NINDS NIH HHS R37 NS029993NINDS NIH HHS R37 NS29993NINDS NIH HHS R56 NS029993
6 · The paper itself

Abstract

background and purposeElevated fibroblast growth factor 23 (FGF23) regulates phosphate homeostasis and is linked with mortality, cardiovascular events, and stroke. However, the role of FGF23 as a risk factor for subclinical cerebrovascular damage is unclear.

methodsWe used multivariable linear and logistic regression to evaluate associations between FGF23, continuously and by quartiles, with white matter hyperintensity volume, expressed as percent intracranial volume (%ICV), and subclinical brain infarction (SBI) in a community-based stroke-free sample.

resultsThere were 1170 stroke-free Northern Manhattan Study (NOMAS) participants with FGF23 levels and quantitative magnetic resonance imaging data on white matter hyperintensity volume and SBI. Participants with FGF23 levels in the top quartile (range=85-1425 RU/mL) had greater white matter hyperintensity volume (β=0.19 %ICV; 95% CI, 0.04-0.33 %ICV; P=0.01) compared with those in the lowest quartile (range=15-49 RU/mL), adjusted for demographics, vascular risk factors, and estimated glomerular filtration rate. These findings remained significant in those without evidence of chronic kidney disease (estimated glomerular filtration rate <60 mL/min per 1.73 m(2)). Elevated FGF23 was not associated with SBI overall after adjusting for demographic factors and estimated glomerular filtration rate, but sex modified the effect of FGF23 on odds of SBI (P for interaction=0.03). FGF23 was associated with significantly greater odds of SBI only in men (odds ratio, 1.7; 95% CI, 1.1-2.7; P=0.03) after full adjustment.

conclusionsThese cross-sectional community-based data from a diverse urban sample show an association between elevated FGF23 and small vessel disease and magnetic resonance imaging-defined brain infarction in men, independent of chronic kidney disease. Data on elevated FGF23 and subclinical cerebrovascular damage progression are needed.

Indexed as

AgedAged, 80 and overBrainCerebrovascular DisordersCross-Sectional StudiesFemaleFibroblast Growth Factor-23Fibroblast Growth FactorsHumansMagnetic Resonance ImagingMaleMiddle AgedRenal Insufficiency, ChronicRisk FactorsSeverity of Illness IndexSex FactorsFGF23 protein, humanFibroblast Growth Factor-23Fibroblast Growth Factorschronic kidney diseasecohort studiesfibroblast growth factor 23leukoaraiosismagnetic resonance imaging (MRI)

Identifiers

PMID26956260
PMCPMC4811730
OpenAlexW2296207885

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.